Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Atherosclerosis Drugs Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The atherosclerosis drugs market size has shown consistent expansion in recent years. It is projected to grow from $50.91 billion in 2025 to $52.45 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.0%. The market’s historical growth can be attributed to the rising prevalence of cardiovascular diseases, enhanced awareness concerning heart health, the adoption of statins and cholesterol-lowering medications, governmental initiatives for cardiovascular care, and the expansion of hospital and retail pharmacy infrastructure.
The atherosclerosis drugs market size is anticipated to demonstrate consistent expansion over the next few years. Its valuation is projected to reach $61.19 billion in 2030, with a compound annual growth rate (CAGR) of 3.9%. This growth throughout the forecast period stems from factors such as the broadening application of precision medicine in cardiovascular treatment, a surge in the adoption of digital health monitoring tools, an increasing demand for combination therapies, the expanding geriatric population, and advancements in new anti-atherosclerosis drug classes. Significant trends for the forecast period include personalized atherosclerosis therapy, combination drug formulations, support for minimally invasive treatments, proactive cardiovascular healthcare, and improved patient adherence coupled with digital monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Atherosclerosis Drugs Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing prevalence of cardiovascular diseases is projected to fuel the expansion of the atherosclerosis drug market. Cardiovascular diseases refer to all conditions impacting the heart and blood vessels, with atherosclerosis specifically involving the buildup of fats, cholesterol, and other substances on a person’s artery walls. This accumulation of plaque inside arteries leads to cardiovascular conditions such as coronary heart disease and stroke. Atherosclerosis drugs are employed to manage cardiovascular diseases by reducing complication risks and addressing underlying issues like elevated cholesterol levels and blood clot formation. For instance, data from January 2024, provided by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the widespread occurrence of cardiovascular diseases will drive the atherosclerosis drug market.
Atherosclerosis Drugs Market Segment Landscape And Growth Outlook
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
#Atherosclerosis Drugs Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies operating in the atherosclerosis drugs market are developing new products, such as anti-inflammatory drugs, to increase their profitability. Atherosclerosis anti-inflammatory drugs are medications specifically designed to mitigate inflammation linked to atherosclerosis, a condition marked by the buildup of plaque in arteries. For instance, in June 2023, AGEPHA Pharma, a Europe-based manufacturer of medical products, launched LODOCO. The U.S. FDA granted approval for LODOCO (colchicine, 0.5 mg tablet) as the pioneering anti-inflammatory atheroprotective cardiovascular treatment. This drug has demonstrated efficacy in lowering the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. LODOCO targets residual inflammation, a key factor in atherosclerotic cardiovascular disease (ASCVD). Approved for use either alone or in conjunction with cholesterol-lowering medications, this drug represents a notable breakthrough in cardiovascular care.
Atherosclerosis Drugs Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.
View The Full Atherosclerosis Drugs Market Report:
Atherosclerosis Drugs Market Largest Region By Revenue And Market Share
North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
